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Abstract
Penile squamous cell carcinoma is a rare disease, in which somatic genetic aberrations
have yet to be characterized. We hypothesized that gene copy aberrations might correlate
with human papillomavirus status and clinico-pathological features. We sought to determine
the spectrum of gene copy number aberrations in a large series of PSCCs and to define
their correlations with human papillomavirus, histopathological subtype, and tumor grade,
stage and lymph node status. Seventy formalin-fixed, paraffin embedded penile squamous
cell carcinomas were centrally reviewed by expert uropathologists. DNA was extracted from
micro-dissected samples, subjected to PCR-based human papillomavirus assessment and
genotyping (INNO-LiPA human papillomavirus Genotyping Extra Assay) and microarray-
based comparative genomic hybridization using a 32K Bacterial Artificial Chromosome
array platform. Sixty-four samples yielded interpretable results. Recurrent gains were
observed in chromosomes 1p13.3-q44 (88%), 3p12.3-q29 (86%), 5p15.33-p11 (67%) and
8p12-q24.3 (84%). Amplifications of 5p15.33-p11 and 11p14.1-p12 were found in seven
(11%) and four (6%) cases, respectively. Losses were observed in chromosomes 2q33-
q37.3 (86%), 3p26.3-q11.1 (83%) and 11q12.2-q25 (81%). Although many losses and
gains were similar throughout the cohort, there were small significant differences observed
at specific loci, between human papillomavirus positive and negative tumors, between
tumor types, and tumor grade and nodal status. These results demonstrate that despite the
diversity of genetic aberrations in penile squamous cell carcinomas, there are significant
correlations between the clinico-pathological data and the genetic changes that may play a
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role in disease natural history and progression and highlight potential driver genes, which
may feature in molecular pathways for existing therapeutic agents.
Introduction
Penile squamous cell carcinoma (PSCC) is a rare disease, but can have a profound physical and
psychological effect on those afflicted. It mainly affects men aged 50–70 years old [1] and,
although rare in developed countries, it is a significant health problem in developing countries.
In Europe and the USA the incidence is less than 1 per 100,000 men, but the age-standardized
rate may be as high as 3.7 and 2.8 per 100,000 in parts of Brazil and Uganda, respectively [2–4].
Penile carcinoma is difficult to treat after metastatic dissemination, given that these tumors are
relatively radio and chemo resistant.
Histologically, PSSCs comprise a spectrum of lesions that differ in clinical behavior. The
most common morphological subtypes of PSCC are usual type (48–65%), basaloid (4–10%),
warty (7–10%) and verrucous (3–8%) [5]. Basaloid carcinomas are the most aggressive PSCC
subtype, whereas verrucous carcinomas have a more indolent clinical course [6].
In comparison to other squamous cell carcinomas, relatively little is known about the
molecular features of PSCC [7–11]. Similar to squamous cell carcinomas of the female lower
genital tract, a subset of PSCCs appears to be driven by HPV. In a recent study analyzing 102
cases [9], HPV DNA was detected in up to 56% of these tumors; however, frequencies ranging
from 14% to 100% have been reported in the literature [12]. The prevalence of HPV infection
seems to correlate with histological type, with HPV DNA reported to be found in up to 76% of
basaloid carcinomas and in only 22% of the indolent verrucous carcinomas [6]. Esophageal
squamous cell carcinomas (OSCCs) also comprise HPV-positive and HPV-negative tumor
types, with the frequency of HPV DNA detection being highly variable in both [6, 9, 13–15],
which may reflect the discrepancies in detection methodology [16]. In oropharyngeal squa-
mous cell carcinoma (OPSCC) HPV positivity confers a good prognosis [17] and better disease
free survival [18] compared to HPV-negative cases. HPV infection has also been well docu-
mented in other squamous cell carcinomas such as vulva and cervical.
There is a paucity of data on the somatic genetic characteristics of PSSCs, possibly due to
the relative rarity of the disease. In England, PSCC services have been managed in supra-spe-
cialized centers in the UK. This has given us the opportunity to accrue a sufficiently sized
cohort to analyze the molecular characteristics of PSCCs. Therefore, we sought to investigate
the repertoire of somatic DNA copy number aberrations in PSSCs, and to determine whether
patterns and types of gene copy number aberrations would correlate with HPV status and clin-
ico-pathological features, including type, grade, stage and HPV status.
Materials and Methods
Cases
We retrieved 70 formalin fixed paraffin embedded PSCCs from the Cellular Pathology Depart-
ment of St George’s Hospital. Cases were reviewed by a panel of expert uropathologists (CC,
BT, RR) for grade, stage (including lymph node status) and subtype using established methods
[19, 20]. Patients’ data were made entirely anonymous and this study was approved by East
London and The City Research Ethics Committee Alpha (The Orchid Tissue Bank; 09/H0704/
4).
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Dissection and DNA Extraction
For all cases, regions of PSCC and normal tissue were marked on the representative sections by
a consultant genitourinary pathologist (DB). Ten to fifteen tissue representative sections were
cut at 10μm thickness from each case and subjected to microdissection under a stereomicro-
scope as previously described [21].
DNA was extracted from microdissected sections using standard phenol-chloroform meth-
ods and its concentration was measured using PicoGreen1 assay as per the manufacturer’s
instructions (Applied Biosystems, Invitrogen, Paisley, UK).
HPV Analysis
The presence of HPV DNA was detected by PCR method using SPF10 primers, which amplify
a 65-bp fragment of the conserved L1 open reading frame and HPV genotypes identified by the
INNO-LiPA HPV Genotyping Extra Assay (Innogenetics NV Ghent, Belgium) as previously
described [9].
Microarray Comparative Genomic Hybridization (aCGH)
DNA extracted from microdissected sections was subjected to microarray-based comparative
genomic hybridization using a 32K bacterial artificial chromosome (BAC) array platform (Her-
nandez et al., 2012) which has been shown to be as robust as, and to have comparable resolu-
tion with, high-density oligonucleotide arrays [22–24]. DNA labeling, array hybridization and
image acquisition were performed as previously described [25].
After filtering polymorphic BACs, a final dataset was produced with unambiguous mapping
information according to build hg19 (NCBI build 37) of the human genome (http://www.
ensemble.org).
Data Analysis
Analyses were performed using the BACE.R R script (R version 2.11.1) was used to pre-process
and analyze the aCGH data as previously described [25, 26].
After filtering polymorphic BACs, a final dataset of 31,367 clones with unambiguous map-
ping information according to build hg19 of the human genome (http://www.ensembl.org) was
smoothed using the circular binary segmentation (cbs) algorithm. A categorical analysis was
applied to the BACs after classifying them as representing amplification (>0.4), gain (>0.08
and0.45), loss (<-0.08), or no change according to their cbs-smoothed Log2 ratio values
[7,10,9]. Threshold values were determined and validated as previously described [21, 26].
Following copy number categorizations for gains, losses or amplifications, Fisher’s exact
tests were performed to identify statistically significant differences (with a false discovery rate-
adjusted p-value< 0.05) in amplifications and gains/ losses between the different subtypes,
grades, stages, HPV associations and nodal status. Adjustment for multiple testing was per-
formed with a step-down permutation procedure (maxT), which provides a robust control of
the family-wise type I error rate (FWER) [27]. Unsupervised hierarchical clustering of cbs-
smoothed ratios, employing Wards clustering algorithm and Euclidean distance metric, was
performed as previously described [26].
Subsequent assessment of the robustness of the cluster analysis was done by assessing the
uncertainty with multiscale bootstrap resampling with the pvclust package in R 3.0.1.
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Results
Patients and Study Samples
Of the 70 PSCC cases, 64 had adequate DNA quality and purity for successful array CGH
analysis.
Demographics including HPV status, stage, grade, lymph node status and histological classi-
fication can be found in Table 1. Genome plots were generated for each case and showed vari-
ous patterns of chromosomal expression. Some examples are as follows: Case 17 (usual type
PSCC), exhibited specific gain/amplification in regions 1p, 3q and 5 (Fig 1A). Case 62 (verru-
cous type PSCC) showed gains in 1q, 2, 3q, 5p and 8q, with obvious amplification in chromo-
some 11p (Fig 1B). Cases 26 (usual type PSCC) and 70 (basaloid type PSCC) also showed gain
in the 3q region; as well as 8q and 13p, respectively (Fig 1C and 1D).
Array CGH and Candidate Driver Genes
PSCCs were shown to harbor many highly recurrent gains, the highest frequencies occurring
on chromosomes 1p13.3-q44 (88%), 3p12.3-q29 (86%), 7p22.3-q36.3 (88%), 8p12-q24.3
(84%), 9p24.3-q34.3 (88%) and 20p13-q13.33 (84%) (Fig 2A, S1 Table). PSCCs also harbored
highly recurrent losses of 2q33-q37.3 (86%), 3p26.3-q11.1 (83%) and 11q12.2-q25 (81%) (Fig
2A, S1 Table). The highest frequency recurrent amplifications were of 3q27.2-q29 (11%) and
8q21.13-q24.3 (23%) (Fig 2B, S1 Table). Our analysis of PSCC samples did not identify dele-
tions or high-level loss of genetic loci and, despite the highly recurrent changes, there were
genetic aberrations that were restricted to only a subset of the cases.
These loci enclose several genes identified in areas of gain, amplification and loss. Gain of
3p12.3-q29 harbor, amongst many other genes, PRKCI, PIK3CA, DCUN1D1, LAMP3 and
RPL35A. The F-box protein, SKP2 (S-phase kinase-associated protein 2) was included in gain
Table 1. Demographics of PSCC cases.
Group for Comparison Subgroup for Comparison Number of Cases
Cancer Type Basaloid 7
Usual 50
Verrucous 7
HPV status Positive 35
Negative 29
Stage Stage 1 4
Stage 2 8
Stage 2A 28
Stage 2B 4
Stage 3 7
Stage 3A 8
Stage 4 5
Grade Grade 1 6
Grade 2 17
Grade 3 41
Nodal Status Nodal N0 31
Nodal N1 16
Nodal N2 13
Nodal N3 2
No information 2
doi:10.1371/journal.pone.0146740.t001
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of 5p15.33-p11 and amplification of 5p15.33-p11 and the oncogene MYC is also highlighted in
the gained region 8p12-q24.3. Amplification of 3q27.2-q29 encompasses the genes PIK3CA,
SENP5 (SUMO1/Sentrin Specific Peptidase 5), CLDN1, TNK2 (tyrosine kinase, non-receptor,
2) and FBXO45 (F-box protein 45). Genes of interest in the amplified region 3q26.1-q27.2
include FNDC3B and ACTL6A/BAF53 (actin-like 6A/BRG1 associated factor 53A). CPT1A,
FGF3/4 and CCND1 are revealed in the amplified region 11p12.-p14.1.
Potential tumor suppressor genes, also found in other squamous cell carcinomas, have been
discovered in the lost regions 2q33-q37.3 (PLCD4), 3p26.3-q11.1 (RBMS3, PLCD1, and CAC-
NA2D3) and 11q12.2-q25 (CPT1A, CCND1, FGF4/FGF3, and PPP2R1B).
HPV Subgroup-Analysis
Firstly, we sought to define whether HPV DNA positive and HPV DNA negative PSSCs would
be underpinned by distinct patterns of gene copy number aberrations. Multi-Fisher's exact test
adjusted for multiple comparisons revealed that HPV-positive and HPV-negative PSCCs have
similar patterns of copy gains and that higher frequencies were demonstrated in 1q, 3q, 5p, 7p
and 8q and amplifications in 3q, 5p and 8q for both HPV-negative and HPV-positive tumors.
Regions of differential gain included 1q, 2p, 7p and 10q, and regions of differential loss on
6p, 11p and q and 17p and q. When an unadjusted p value was used, 17p loss was exhibited
with an increased frequency in the HPV negative group (p<0.05), but other areas of differential
gain and loss showed no pattern of association with either the HPV positive or negative group.
When p values were adjusted, regions with a statistically significant higher frequency of cases
in HPV positive cohort exhibited gain on 1q (151,622,431–151,793,285; p = 0.035). When p
values were adjusted, regions with a statistically significant higher frequency of cases in HPV
negative cohort exhibited gain of 2p (60,835,599–61,089,333; p = 0.034), 7p (48,668,454–
Fig 1. Microarray-based comparative genomic hybridisation analysis invasive penile squamous cell carcinoma components.Genome plots
obtained with the 32K bacterial artificial chromosome array platform for: (A) Case 17 (usual type), (B) Case 62(verrucous), (C) Case 26 (usual type) and (D)
Case 70 (basaloid).
doi:10.1371/journal.pone.0146740.g001
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49,846,998; 0.034), 10q (108,751,067–109,429,862; p = 0.047) and loss of 11p (46,103,041–
47,520,939; p<0.05). No significant differences in the prevalence of specific amplified loci were
identified. Hierarchical cluster analysis failed to demonstrate a clear difference in clustering of
genetic change between HPV-positive and HPV-negative tumors (Figs 2C and 3).
Further Clinico-Pathological Subgroup-Analysis
In addition, we conducted further analysis based on other defined clinic-pathological variables
(for details of specific gene loci, see S2 Table). Analysis of histological subtypes uncovered dif-
ferential gain of regions on 1q (p<0.05) and 3q(p = 0.04, region close to telomere), differential
loss of 11p and q (p<0.05, close to telomere), 13q (p = 0.03), 15q (p = 0.03), 16q (p = 0.02), and
differential amplification of 3q and 8q (p<0.05), when comparing basaloid to non-basaloid
subtypes (Fig 4). In regions of these chromosomes statistically significant gain, loss and ampli-
fication were shown in more cases in the non-basaloid group compared to the basaloid group.
Comparing verrucous cases to non-verrucous differential loss was discovered on 11p and 17q
(p<0.05), in significantly more cases in the non-verrucous than verrucous cohort. No signifi-
cant differences in the prevalence of specific gained or amplified loci were identified.
Fig 2. Samples of invasive penile squamous cell carcinoma. (A) Frequency plot of copy number gains and losses. (B) Frequency plot of high level gain or
amplification. (C) Hierarchical cluster analysis for all cases comparing stage, HPV status, subtype, grade and nodal status. The proportion of tumors in which
each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (y axis) for each BAC clone according to its genomic
position (x axis).
doi:10.1371/journal.pone.0146740.g002
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Comparing usual type to non-usual type, differential loss was found on 3p (p<0.05) and 17q
(unadjusted p<0.05, adjusted p = 0.1–0.33). Interestingly there were no significant differences
in the prevalence of specific gained or amplified loci were identified.
A supervised analysis of the aCGH results according to histological grade revealed differen-
tial gains in chromosome 6p and differential losses in chromosomes 2p, 5p and q, 8q and 11p.
Gains of 6p were more frequently found in tumors of a low histological grade (i.e. 1 and 2)
than in high-grade lesions (i.e. 3), but this was not statistically significant when adjusted p val-
ues were calculated. Loss of 2p and 5p and q were significantly more frequently found in low-
Fig 3. HPV status of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ high level gain in HPV positive and HPV
negative PSCC samples. The proportion of tumors in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is
plotted (y axis) for each BAC clone according to its genomic position (x axis).
doi:10.1371/journal.pone.0146740.g003
Fig 4. Histological subtype of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ high level gain in Basaloid and
non-basaloid PSCC samples. The proportion of tumors in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is
plotted (y axis) for each BAC clone according to its genomic position (x axis).
doi:10.1371/journal.pone.0146740.g004
Penile Cancer Genetics
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grade lesions (p<0.05). Loss of 8q and 11p were significantly more frequently found in high-
grade tumors (p<0.05). No significant differences in the prevalence of specific amplified loci
were identified (Fig 5).
PSSCs of different stages displayed distinct patterns of differential loss on 5q (p = 0.03), 6p
(p<0.01) and 18p, as well as amplification of 8q (Fig 6). These aberrations were significantly
more frequently found in tumors of high histological stage (i.e. 3 and 4) than in low stage
lesions (i.e. 1 and 2). No significant differences in the prevalence of specific gained loci were
identified.
Analysis of aCGH data according to nodal status (N0, N1, N2, and N3) yielded more fre-
quent gain of 7q and loss of 2pq (p<0.05), 4q (p = 0.03), 9q (p<0.05), 10q (p<0.05), 11q
(p<0.05), 15q (p<0.05) and 20p (p<0.05) in node negative cases compared to node positive
cases (Fig 7). For 7q this was not statistically significant when an adjusted p value was calcu-
lated (unadjusted p = 0.001–0.04; adjusted p = 0.24–0.6). No significant differences in the prev-
alence of specific amplified loci were identified.
Given the diversity of gene copy number aberrations of PSSCs, we performed class discovery
analysis using hierarchical clustering. There were stable clusters, but none showed enrichment
for a particular clinico-pathological feature (Fig 2C).
Discussion
We have provided a detailed characterization of the genetic landscape of prostate cancer by
DNA copy number aberrations found in HPV-positive and HPV-negative PSCCs, and demon-
strated that these tumors display similar patterns of genetic aberrations despite the distinct
pathogenetic mechanisms, with statistically significant changes in only a few small loci. It has
been documented that HPV changes cell physiology inactivating RB and p53 pathways [28, 29]
and our genomic data shows copy number loss at 13q12.11-q34 (80% of HPV positive cases)
and 17p13.3-p11.1 (63% of HPV positive cases), harboring RB1 and TP53 genes, respectively.
However, these changes were not statistically significant in their difference from the HPV nega-
tive cohort. It is possible that TP53 and RB1 may be mutated in the cases without HPV infec-
tion. Further investigation, such as mutational analysis, will be required to elucidate this.
Another mechanism of TP53 pathway inactivation includes amplification/overexpression of
an ubiquitin ligase, MDM2 (murine double minute 2). TP53 is usually kept at low levels by
MDM2 in normal cells. MDM2 and TP53 form an auto-regulatory negative-feedback loop, in
which TP53 induces the expression of MDM2, which then facilitates the breakdown of TP53 in
the nucleus and cytoplasm, inhibits its transcriptional activity and assists its nuclear export
[30]. Our data did not support this, as we failed to find any differential gain or differential
amplification of this gene at 12q15 in the HPV cohorts, or amplification in the overall data.
However, an earlier small genomic study confirmed amplification on 12q, but only in 4.3% of
PSCC cases, which encompasses the MDM2 gene [7]. pRB1 pathway inactivation could also be
caused by gains/ amplification of CCNE1, CCND1, CDK2 and CDK4, but our data did not
show differential copy number change at the corresponding loci between the HPV positive and
HPV negative cohorts. However, gain of the regions encompassing CCNE1 (19p13.11-q13.43;
71% cases) and CCND1 (11q12.2-q14.1; 46% cases) were found in the HPV positive group,
and both gain and amplification of the region incorporating CCND1 (11q13.3-q13.4; 20% and
3% cases, respectively) were found in the HPV negative group.
One previous paper has been published on the pattern and repertoire of somatic genetic
aberrations in PSSCs.[7] Alves et al investigated the chromosomal changes found in 26 PSCCs
using a spread of metaphase chromosomes on a microscope slide as a hybridization target, pre-
pared as in fluorescence in situ hybridization. In three cases no DNA copy number alterations
Penile Cancer Genetics
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were detected, but contamination of the PSCC samples with normal tissue could not be
excluded. Alves et al. observed the most common copy number gains on 8q24 (48%), 16p11–
12(48%), and 20q11–13 (48%); 22q (43%); 19q13 (39%) and 5p15 (35%). In comparison, our
data demonstrated copy number gains in similar overlapping regions on chromosomes
8p12-q24.3 (84%), 16p11.2-q24.3 (77%), 20p13-q13.3 (84%), 22q11.1–13.3 (73%),
19p13.11-q13.43 (64%) and 5p15.33-q11.2 (67%). Losses were found by the Alves group on
15q, 16q, 21q and 20p. PSCC cases exhibited loss on p and q arms of all other chromosomes,
excluding chromosomes 22 and Y, which did not show loss. We showed amplifications of
1q32.2 (6%), 3q27.2-q29 (11%), 3q26.1-q27.2 (8%), 5p15.2-p14.3 (9%), 5p14.3-p11 (8%),
Fig 5. Histological grade of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ high level gain in high grade (3) and
low grade (1–2) PSCC samples. The proportion of tumors in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars)
is plotted (y axis) for each BAC clone according to its genomic position (x axis).
doi:10.1371/journal.pone.0146740.g005
Fig 6. Clinical Stage of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ high level gain in high stage (3–4) and
low stage (1–2) PSCC samples. The proportion of tumors in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars)
is plotted (y axis) for each BAC clone according to its genomic position (x axis).
doi:10.1371/journal.pone.0146740.g006
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5p15.33-p15.2 (6%), 8q21.13-q24.3 (23%) and 11p14.1-p12 (6%), none of which corresponded
to the single amplified case in the Alves data set (37%). Deletions were confirmed by Alves
et al. at 13q21–22 (43%) and 4q21–32 (30%), but our study did not detect deletions in any
cases. The number of gene copy number aberrations was reported to be numerically associated
with ‘shorter survival’ in Alves et al., but it was not made clear whether this was disease-free,
disease-specific or overall survival. Our study did not assess survival data for comparison with
this. Given the relatively low resolution of the methods employed by Alves et al. and lack of
information on the HPV status of the tumors analyzed in their study, it is difficult to grasp the
overall clinical and biological significance of their data. However, a more recent study utilizing
aCGH describes copy number alterations in PSCCs and supports the hypothesis that PSCCs
manifest different aetiologies according to viral status.[31]
Our current data has highlighted patterns of copy number gains, losses and amplifications
in a PSCC cohort that bear some similarities to those in other HPV related squamous cell carci-
nomas (Table 2). For example, gains and amplifications on chromosomes 3q, 8q, 11pq and 5p,
and losses on 3p and 4q are shared many squamous cell carcinomas. Gain of 3p12.3-q29 in our
study harbors PIK3CA, which codes for the p110α subunit of PI3-kinase, as part of the PI3-ki-
nase/AKT signaling pathway. It plays a key function in the regulation of cell growth and apo-
ptosis, and it has been associated with cervical, head and neck and upper esophageal squamous
cell carcinomas [32]. Also located in this region is PRKCI, a member of the protein kinase C
(PKC) family of serine/threonine protein kinases involved in a wide variety of cellular pro-
cesses and it has been associated with lymph node metastases in OSCC [33].
Within other gained (5p15.33-p11) and amplified (5p15.33-p11) lies SKP2. It comprises the
substrate recognition unit of the SCFSKP2 ubiquitin ligase complex and has been involved in
the ubiquitin driven breakdown of cyclin dependent kinase inhibitor p27 (a dosage dependent
tumor suppressor protein), which is an important regulator of G1 progression. Increased levels
of expression have been demonstrated in squamous and non squamous cell carcinomas and it
has been linked with tumor progression and poor prognosis [34–37]. Apart from PIK3CA,
Fig 7. Lymph node status of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ high level gain in lymph node
positive and lymph node negative PSCC samples. The proportion of tumors in which each bacterial artificial chromosome (BAC) clone is gained (green bars)
or lost (red bars) is plotted (y axis) for each BAC clone according to its genomic position (x axis).
doi:10.1371/journal.pone.0146740.g007
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amplification of 3q27.2-q29 also encompasses SENP5, CLDN1 and TNK2. SENP5 is a SUMO
(small ubiquitin-like modifier) specific protease. The addition of SUMO proteins is responsible
for the reversible post translational modification of proteins. SUMOS are conjugated to cellular
regulators, which changes the localization, activity and stability of the substrates. SENP5 plays
an important role in many cancer types, including esophageal squamous cell carcinoma [38].
CLDN1 is a member of a family of principal proteins important for tight junction formation
and function. CLDN1 has been detected at significantly increased levels in cervical cancer,
compared to normal cervical epithelium, and has been implicated in cervical cancer progres-
sion. TNK2 is a ubiquitously expressed non-receptor tyrosine-protein and serine/threonine-
protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and
proliferation. TNK2 forms a robust complex with all isoforms of AKT and directly regulates
AKT's plasma membrane recruitment, thereby bypassing the PI3-kinase pathway. This process
is facilitated by a novel phosphorylation event in AKT, Tyrosine 176 that is invariant from
yeast to mammals. TNK2 gains have been found in breast, prostate, lung, pancreas, brain,
Ewing’s sarcoma and the pharmaceutical agent dasatinib is a known inhibitor [39].
FBXO45 binds to TP73, a pro-apoptotic gene, and initiates its proteosome dependent degra-
dation [40]. FNDC3B is contained in the amplified region 3q26.1-q27.2, inducing the epithe-
lial-to-mesenchymal transition (EMT) and activating several cancer pathways, including
PI3-kinase/Akt, RB1 and TGFβ signaling [41]. CPT1A is an isoform of carnitine palmitoyl
transferase 1 that has been demonstrated to interact with BCL2 [42]. Some of these potential
driver genes exist as part of molecular pathways for which therapeutic agents are either already
in use or are in various stages of clinical trials.
Focusing on our HPV subgroup, we showed gain of 1q to be more frequent in HPV-positive
cases and gain of 2p, 7p and 10q, as well as loss of 11p to be more frequent in HPV-negative
cases. Only a subset of the data on other squamous cell carcinomas includes HPV DNA analy-
sis, but not all findings are in concordance with those of PSCC. For example, Yangling et al.
found gain of 3q and 12q to be more common in HPV-positive VSCC cases and gain of 8q
more common in HPV-negative [43]. Differences were also seen in comparison of HPV
cohorts in oropharyngeal squamous cell carcinomas [18, 44], which highlighted Xp gain and
16q loss more common in HPV-positive cases, and 3p, 5q, 9p, 15q and 18q loss more common
in HPV-negative cases [18]. In contrast to these studies, a higher frequency of 1q gain in our
HPV-positive cohort is in accordance with HPV-positive VSCCs [45] and CSCCs [46–48].
Further analysis by Jung et al. also demonstrated a distinction between HPV-positive (DNA/
RNA positive) and HPV-negative (DNA/RNA negative and DNA-positive/RNA-negative)
tumors, with clustering of the HPV-positive group, which was not reflected in our PSCC data.
Although there is lack of gross correlation between genetic copy number change and HPV
status, more detailed analysis of PSCCs may reveal more striking differences between the HPV
groups, as disclosed by next-generation sequencing in patients with head and neck squamous
cell carcinoma that showed more mutations in HPV-negative than HPV-positive tumors [49],
as well as recent analysis of esophageal epithelial cell lines in vitro suggests that HPV infectivity
was independent of inflammation and may play a less significant role than first thought [14].
In addition, lymph node metastases were associated with chromosomal amplifications in
OSCC at 2q12–14, 3q24–26, and 7q21–31, while distant metastasis correlated to amplification
at 7p13–21 [50]. This is in contrast to our data that highlighted higher frequency of statistically
significant losses in lymph node negative PSCCs. As lymph node status is a marker of progno-
sis in PSCC, given further analysis, these genetic aberrations may have implications with regard
to development of early molecular prognostic indicators. The statistically significant, small
genetic differences in high stage PSCC also highlight potential targets for further analysis of
PSCC progression.
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The differences in genomic profile between PSCCs and other HPV related squamous cell
carcinomas may, in part, be attributed to intrinsic genetic differences, the different methods of
CGH used or the number of cases analyzed.
Conclusion
It has long been suggested that SCCs in different locations may develop through similar molec-
ular pathways and that HPV and non-HPV pathways are responsible in the pathogenesis of
PSCC. The correlations between the clinico-pathological data and copy number aberrations in
our study supports this, but with the differences in genetic aberrations between PSCCs and
other types of squamous cell carcinomas this remains unproven. Nonetheless, the correlations
demonstrated here could play an important role in PSCC natural history and progression and
highlight potential driver genes, which may feature in molecular pathways for existing thera-
peutic agents.
Further analysis of PSCCs would need to be conducted to establish whether or not there is a
final common pathway of HPV and non-HPV associated PSCCs and this would need to
include next generation sequencing, cell culture studies, acquisition of paired genetic informa-
tion from metastatic lymph node tissue and correlation with survival data.
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